{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Adenocarcinoma%2C+Pancreatic+Ductal&page=7", "query": { "condition": "Adenocarcinoma, Pancreatic Ductal", "page": 7 }, "page_size": 10 }, "pagination": { "page": 7, "page_size": 10, "total_count": 404, "total_pages": 41, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Adenocarcinoma%2C+Pancreatic+Ductal&page=8&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Adenocarcinoma%2C+Pancreatic+Ductal&page=6&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-13T22:08:28.333Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04657068", "title": "A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Cancer", "Metastatic Cancer", "Ovarian Cancer", "Primary Peritoneal Cancer", "Fallopian Tube Cancer", "Endometrial Cancer", "Metastatic Colorectal Cancer", "Pancreatic Ductal Adenocarcinoma", "Acinar Cell Carcinoma" ], "interventions": [ { "name": "ART0380", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Artios Pharma Ltd", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 542, "start_date": "2021-01-27", "completion_date": "2028-06", "has_results": false, "last_update_posted_date": "2026-07-30", "last_synced_at": "2026-10-13T22:08:28.333Z", "location_count": 41, "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 33 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Los Angeles", "state": "California" }, { "city": "Santa Barbara", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04657068" }, { "nct_id": "NCT05630989", "title": "A Registry to Capture Patient Outcomes With KRAS G12R Altered Advanced Pancreatic Ductal Adenocarcinoma Treated With MEK Inhibitor-based Combination Therapy", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Pancreatic Ductal Adenocarcinoma" ], "interventions": [ { "name": "combination therapy with no MEKi", "type": "OTHER" }, { "name": "combination therapy with MEKi-HCQ", "type": "DRUG" }, { "name": "combination therapy with MEKi-EGFRi", "type": "DRUG" }, { "name": "combination therapy with MEKi.", "type": "DRUG" } ], "intervention_types": [ "OTHER", "DRUG" ], "sponsor": "Mandana Kamgar, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 80, "start_date": "2023-02-07", "completion_date": "2027-08-01", "has_results": false, "last_update_posted_date": "2026-05-05", "last_synced_at": "2026-10-13T22:08:28.333Z", "location_count": 1, "location_summary": "Milwaukee, Wisconsin", "locations": [ { "city": "Milwaukee", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT05630989" }, { "nct_id": "NCT06625320", "title": "Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Pancreatic Cancer", "PDAC", "PDAC - Pancreatic Ductal Adenocarcinoma" ], "interventions": [ { "name": "RMC-6236", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "nab-paclitaxel", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" }, { "name": "Liposomal irinotecan", "type": "DRUG" }, { "name": "5-fluorouracil", "type": "DRUG" }, { "name": "leucovorin", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Revolution Medicines, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 500, "start_date": "2024-10-16", "completion_date": "2027-12", "has_results": false, "last_update_posted_date": "2026-06-02", "last_synced_at": "2026-10-13T22:08:28.333Z", "location_count": 37, "location_summary": "Gilbert, Arizona • Phoenix, Arizona • Duarte, California + 31 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06625320" }, { "nct_id": "NCT04150042", "title": "SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem Cells", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Pancreatic Adenocarcinoma Metastatic", "BRCA1 Mutation", "BRCA2 Mutation", "Pancreatic Acinar Cell Carcinoma", "Pancreatic Ductal Adenocarcinoma", "Pancreatic Cancer", "Metastatic Pancreatic Cancer", "Metastatic Pancreatic Ductal Adenocarcinoma", "Breast Cancer Metastatic", "Breast Cancer Stage IV", "Pancreatic Cancer Stage IV", "HER2-negative Breast Cancer", "HER2 Negative Breast Carcinoma", "Adenocarcinoma of the Breast", "PALB2 Gene Mutation", "Pancreas Cancer, Metastatic", "Pancreas Cancer, Recurrent", "Pancreas Cancer", "Stage IV Pancreatic Cancer", "Stage 4 Pancreatic Cancer" ], "interventions": [ { "name": "Melphalan", "type": "DRUG" }, { "name": "BCNU", "type": "DRUG" }, { "name": "Vitamin B12B", "type": "DRUG" }, { "name": "Vitamin C", "type": "DRUG" }, { "name": "Autologous Hematopoietic Stem Cells", "type": "DEVICE" } ], "intervention_types": [ "DRUG", "DEVICE" ], "sponsor": "General Oncology, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2021-01-13", "completion_date": "2028-12", "has_results": false, "last_update_posted_date": "2026-01-29", "last_synced_at": "2026-10-13T22:08:28.333Z", "location_count": 2, "location_summary": "Boston, Massachusetts • New York, New York", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04150042" }, { "nct_id": "NCT04390763", "title": "Study of Efficacy and Safety of NIS793 (With and Without Spartalizumab) in Combination With SOC Chemotherapy in First-line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Pancreatic Ductal Adenocarcinoma" ], "interventions": [ { "name": "NIS793", "type": "BIOLOGICAL" }, { "name": "Spartalizumab", "type": "BIOLOGICAL" }, { "name": "gemcitabine", "type": "DRUG" }, { "name": "nab-paclitaxel", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 164, "start_date": "2020-10-16", "completion_date": "2024-05-02", "has_results": true, "last_update_posted_date": "2025-10-16", "last_synced_at": "2026-10-13T22:08:28.333Z", "location_count": 5, "location_summary": "Atlanta, Georgia • Baltimore, Maryland • Boston, Massachusetts + 1 more", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT04390763" }, { "nct_id": "NCT05632328", "title": "AGEN1423 and Botensilimab w/ or w/o Chemo in PDAC", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Pancreatic Ductal Adenocarcinoma", "Pancreatic Ductal Adenocarcinoma", "Pancreatic Cancer" ], "interventions": [ { "name": "AGEN1423", "type": "DRUG" }, { "name": "Botensilimab", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Nab-paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bruno Bockorny", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2024-08-08", "completion_date": "2027-04-01", "has_results": false, "last_update_posted_date": "2026-07-09", "last_synced_at": "2026-10-13T22:08:28.333Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT05632328" }, { "nct_id": "NCT02790944", "title": "Utilizing a Multi-gene Testing Approach to Identify Hereditary Pancreatic Cancer", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Pancreatic Ductal Adenocarcinoma" ], "interventions": [ { "name": "Multi-gene Next Generation Sequencing Panel", "type": "GENETIC" } ], "intervention_types": [ "GENETIC" ], "sponsor": "Ambry Genetics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "89 Years", "sex": "ALL", "summary": "18 Years to 89 Years" }, "enrollment_count": 300, "start_date": "2016-05-04", "completion_date": "2020-08-15", "has_results": false, "last_update_posted_date": "2020-08-25", "last_synced_at": "2026-10-13T22:08:28.333Z", "location_count": 3, "location_summary": "Scottsdale, Arizona • Boston, Massachusetts • Pittsburgh, Pennsylvania", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT02790944" }, { "nct_id": "NCT04117087", "title": "Pooled Mutant KRAS-Targeted Long Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Resected Mismatch Repair Protein (MMR-p) Colorectal and Pancreatic Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Colorectal Cancer", "Pancreatic Cancer" ], "interventions": [ { "name": "KRAS peptide vaccine", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" }, { "name": "Ipilimumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 27, "start_date": "2020-05-28", "completion_date": "2027-06-01", "has_results": false, "last_update_posted_date": "2026-07-27", "last_synced_at": "2026-10-13T22:08:28.333Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT04117087" }, { "nct_id": "NCT02732938", "title": "Ph1b/2 Study of PF-04136309 in Combination With Gem/Nab-P in First-line Metastatic Pancreatic Patients", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Pancreatic Ductal Adenocarcinoma" ], "interventions": [ { "name": "PF-04136309", "type": "DRUG" }, { "name": "Nab-paclitaxel", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 22, "start_date": "2016-05-04", "completion_date": "2017-10-10", "has_results": true, "last_update_posted_date": "2019-02-04", "last_synced_at": "2026-10-13T22:08:28.333Z", "location_count": 18, "location_summary": "Boston, Massachusetts • New York, New York • Rochester, New York + 6 more", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02732938" }, { "nct_id": "NCT05432193", "title": "FAPi Radioligand OpeN-Label, Phase 1 Study to Evaluate Safety, Tolerability and DosImetry of [Lu-177]-PNT6555; A Dose Escalation Study for TReatment of Patients With Select Solid Tumors (FRONTIER)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Pancreatic Ductal Adenocarcinoma", "Colorectal Cancer", "Esophageal Cancer", "Melanoma (Skin)", "Soft Tissue Sarcoma", "Head and Neck Squamous Cell Carcinoma", "Cholangiocarcinoma" ], "interventions": [ { "name": "[Ga-68]-PNT6555", "type": "DRUG" }, { "name": "[Lu-177]-PNT6555", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2022-07-13", "completion_date": "2024-10-02", "has_results": false, "last_update_posted_date": "2025-06-25", "last_synced_at": "2026-10-13T22:08:28.333Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05432193" } ] }